Can a higher dose of adenosine sharpen heart scans?
NCT ID NCT06578234
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This trial is testing whether a higher dose of adenosine, a drug used during cardiac MRI to stress the heart, improves blood flow imaging compared to the standard dose. The study includes 180 adults with suspected or known coronary artery disease or heart failure. By comparing the two doses, researchers hope to reduce false results and improve diagnosis and treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Adenosine
- What this could lead to
- If high-dose adenosine works better, it could improve the accuracy of cardiac MRI stress tests, leading to better diagnosis and treatment decisions for people with coronary artery disease.
- What could go wrong
- This is a phase 4 trial, but it's still testing a dose difference that may not show a clear benefit. High-dose adenosine may cause more side effects like chest discomfort or shortness of breath.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 180 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patients: 1. The subject has given their written consent to participate in the trial. 2. Are referred to Department of Clinical Physiology, Skåne University Hospital, for suspected or known CCS or heart failure 3. Matches the inclusion criteria for sex and age (6 females and 6 males from each group in each age decade from 40 to \>80 years old) 4. Matches the inclusion criteria for no known heart failure (group b) or known heart failure (group c) 5. No caffein intake \<24h prior to the examination Healthy volunteers: 1. The subject has given their written consent to participate in the trial. 2. Matches the inclusion criteria for sex and age (6 females and 6 males from each group in each age decade from 40 to \>80 years old) 3. No caffein intake \<24h prior to the examination Exclusion Criteria: Patients: 1. Acute referral (in-house patients) 2. Clinically unstable 3. Acute chest pain 4. Severe or decompensated heart failure 5. Non sinus rhythm (e.g. atrial fibrillation) 6. Asthma or severe chronic obstructive pulmonary disease 7. Known chronic renal failure (eGFR \<45mL/min/1.73m2) 8. AV-block II or III 9. Left Bundle Branch Block 10. Systolic blood pressure \<90 mmHg or \>230 mmHg at rest 11. Increased intracranial pressure 12. Known allergy or adverse reaction to adenosine or mannitol 13. Known allergy or adverse reaction to gadolinium contrast agents 14. Treatment with medication containing dipyradimol or teofyllamin/teofyllin 15. Claustrophobia 16. Devices contraindicated to CMR imaging (pacemaker, implants, intracranial clips etc) 17. Pregnancy or breast feeding (screened by question only) 18. Inability to give informed consent due to mental state, language difficulties etc Healthy volunteers: 1. Any of the exclusion criteria for patients 2. Blood pressure \> 140/90 measured according to clinical routine 3. Known systemic disease 4. Known cardiac disease 5. Cardiovascular medication 6. Medication that might influence cardiovascular health 7. Smoking
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic coronary syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Clinical Physiology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital
RECRUITINGLund, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Heart bypass surgeons test which vein layout keeps grafts open
- A soft patch that watches your heart beat in real time
- Can daily mindful breathing ease heart failure symptoms?
- Can a smartphone app keep heart failure patients out of the hospital?
- Zapping the ear: a new way to stop Post-Surgery heart rhythm problems?